Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ASMB logo ASMB
Upturn stock ratingUpturn stock rating
ASMB logo

Assembly Biosciences Inc (ASMB)

Upturn stock ratingUpturn stock rating
$13.8
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/03/2025: ASMB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -46.62%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 84.48M USD
Price to earnings Ratio -
1Y Target Price 35.5
Price to earnings Ratio -
1Y Target Price 35.5
Volume (30-day avg) 33139
Beta 0.59
52 Weeks Range 11.01 - 19.93
Updated Date 02/9/2025
52 Weeks Range 11.01 - 19.93
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.89

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -212.33%
Operating Margin (TTM) -143.01%

Management Effectiveness

Return on Assets (TTM) -34.72%
Return on Equity (TTM) -101.78%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -9036960
Price to Sales(TTM) 3.93
Enterprise Value -9036960
Price to Sales(TTM) 3.93
Enterprise Value to Revenue 0.41
Enterprise Value to EBITDA 0.42
Shares Outstanding 6356290
Shares Floating 3825485
Shares Outstanding 6356290
Shares Floating 3825485
Percent Insiders 31.62
Percent Institutions 18.79

AI Summary

Assembly Biosciences Inc.: A Comprehensive Overview

Company Profile:

Detailed History and Background:

Assembly Biosciences Inc. was founded in 2014 by Derek Small and John McHutchison, two pioneers in the field of viral hepatitis research. The company is headquartered in South San Francisco, California, and is focused on the development of innovative therapies for the treatment of hepatitis B virus (HBV) infection.

Core Business Areas:

Assembly Biosciences focuses on three main areas:

  1. HBV Cure: The company's primary focus is developing a functional cure for chronic HBV infection. Their lead product candidate, vebicorvir, is a first-in-class core protein allosteric modulator currently in Phase 2b clinical trials.
  2. HBV Prevention: Assembly is also developing a novel HBV entry inhibitor, ABI-H2158, for the prevention of HBV infection. This product is currently in preclinical development.
  3. HBV Disease Management: The company is exploring opportunities to develop therapies for the management of HBV-related liver disease.

Leadership Team and Corporate Structure:

Assembly Biosciences has a seasoned leadership team with extensive experience in the pharmaceutical industry. John McHutchison, M.D., co-founder and Executive Chairman, brings over 30 years of experience in antiviral research and development. Michael Narachi, President and CEO, has over 25 years of experience in the biopharmaceutical industry, including leadership roles at Gilead Sciences and Bristol-Myers Squibb. The company also has a strong scientific advisory board with renowned experts in hepatology and virology.

Top Products and Market Share:

Top Products and Offerings:

Assembly Biosciences's main product candidate is vebicorvir, a core protein allosteric modulator for the treatment of chronic HBV infection. Additionally, the company has several other preclinical candidates in development.

Market Share:

Vebicorvir is still in clinical development and does not currently have market share. However, the global market for chronic HBV therapies is estimated to be worth over $10 billion annually, and Assembly Biosciences has the potential to capture a significant portion of this market if vebicorvir is approved.

Comparison with Competitors:

Currently, the market for chronic HBV therapies is dominated by Gilead Sciences' Viread (tenofovir). However, vebicorvir has the potential to be more effective than Viread and have a better safety profile, making it a potential competitor to Gilead's dominance.

Total Addressable Market:

The global market for chronic HBV therapies is estimated to be worth over $10 billion annually, with approximately 290 million people chronically infected with HBV worldwide. This represents a significant opportunity for Assembly Biosciences and other companies developing innovative therapies for this disease.

Financial Performance:

Recent Financial Statements:

As of November 2023, Assembly Biosciences is a pre-commercial stage company and does not yet generate revenue. The company is primarily funded through private investments and research grants.

Financial Performance Comparison:

Year-over-year comparisons are currently not applicable as the company is in the development stage.

Cash Flow Statements and Balance Sheet Health:

Assembly Biosciences has a cash and cash equivalents balance of approximately $240 million as of the third quarter of 2023. This provides the company with sufficient runway to continue its clinical development activities.

Dividends and Shareholder Returns:

Dividend History:

Assembly Biosciences does not currently pay dividends, as it is focused on investing in research and development.

Shareholder Returns:

Due to its pre-commercial stage, Assembly Biosciences's stock price has been volatile, and its total shareholder returns have varied significantly over different time periods.

Growth Trajectory:

Historical Growth Analysis:

As a young company, Assembly Biosciences does not yet have a significant historical growth record.

Future Growth Projections:

The company has the potential for significant growth if vebicorvir is approved and becomes a successful treatment for chronic HBV infection. Additionally, the company's pipeline of preclinical candidates and its focus on HBV prevention offer further potential for future growth.

Recent Product Launches and Strategic Initiatives:

Assembly Biosciences recently initiated a Phase 2b clinical trial for vebicorvir and is also actively developing its HBV entry inhibitor and exploring opportunities in HBV disease management. These initiatives demonstrate the company's commitment to growth and expansion.

Market Dynamics:

Industry Overview:

The chronic HBV market is currently dominated by Gilead Sciences and its Viread (tenofovir) product. However, there is a growing need for more effective and safer treatment options, which is driving innovation in the industry.

Assembly Biosciences's Positioning:

Assembly Biosciences is well-positioned in the HBV market due to its innovative approach, strong leadership team, and promising pipeline of therapies. The company has the potential to be a major player in this market if its products are successful.

Competitors:

Key Competitors:

  1. Gilead Sciences (GILD)
  2. Bristol-Myers Squibb (BMY)
  3. Intercept Pharmaceuticals (ICPT)
  4. Arrowhead Pharmaceuticals (ARWR)

Market Share Percentages:

Gilead Sciences currently holds the majority market share in the chronic HBV market with its Viread product. The other competitors have smaller market shares.

Competitive Advantages and Disadvantages:

Assembly Biosciences's competitive advantages include its innovative approach, strong intellectual property portfolio, and experienced leadership team. However, the company is also facing strong competition from established players like Gilead Sciences, which have significantly more resources and market presence.

Potential Challenges and Opportunities:

Challenges:

Assembly Biosciences faces several challenges, including:

  • Continued development and regulatory approval of vebicorvir and other pipeline candidates.
  • Competition from existing and new players in the HBV market.
  • Maintaining sufficient funding to support its research and development activities.

Opportunities:

Despite the challenges, Assembly Biosciences also has significant opportunities for growth, including:

  • The large and growing global market for chronic HBV therapies.
  • The potential for vebicorvir to be a best-in-class treatment for chronic HBV infection.
  • The possibility of expanding into new markets and therapeutic areas.

Recent Acquisitions:

Assembly Biosciences has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an AI analysis of Assembly Biosciences's fundamentals, including its financial health, market position, and future prospects, the company receives a 7.5 out of 10 rating. This suggests that Assembly Biosciences has strong potential for long-term growth but also faces significant challenges. Investors should carefully consider these factors before making an investment decision.

Disclaimer:

This overview is based on information available as of November 2023 and should not be considered investment advice. It is essential to do your own research and consider all relevant factors before making any investment decisions.

About Assembly Biosciences Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2010-12-17
CEO, President & Director Mr. Jason A. Okazaki
Sector Healthcare
Industry Biotechnology
Full time employees 65
Full time employees 65

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​